MGF / PEG-MGF

Mechano Growth Factor · IGF-1Ec · PEGylated MGF · C-domain peptide

"The IGF-1 splice variant your muscles produce in response to mechanical stress — a localised repair signal with a ~5 minute half-life in its native form. PEG-MGF pegylates it to extend activity to several days. Acts through a receptor distinct from IGF-1R, driving satellite cell activation at the site of damage rather than systemically. The bodybuilder's tissue repair peptide."

Origin
IGF-1Ec splice variant of the IGF-1 gene
Half-life
~5 min (MGF) · days (PEG-MGF)
Mechanism
Non-IGF-1R pathway · satellite cell activation
Use
Local muscle repair · injury recovery · hypertrophy
WADA
Prohibited at all times
Origin & Background

The muscle's own damage repair signal

Mechano Growth Factor (MGF) is an alternatively spliced isoform of the IGF-1 gene — specifically the IGF-1Ec isoform produced when the IGF-1 gene is spliced in response to mechanical stress or tissue damage. When you train, tear muscle fibres, or sustain an injury, the local tissue upregulates this specific splice variant to initiate repair. It is the body's own localised muscle repair signal, distinct from the systemic IGF-1 produced by the liver in response to GH.

The critical distinction from IGF-1 LR3: MGF acts primarily through a receptor separate from IGF-1R — likely involving the extracellular signal domain of the E-peptide — and drives satellite cell activation through the MAPK-Erk1/2 pathway independently of the PI3K/Akt pathway that dominates IGF-1R signalling. This means MGF and IGF-1 are not redundant — they stimulate different aspects of the repair and hypertrophy process and can be used together synergistically.

The problem with native MGF is its ~5 minute half-life — almost useless for systemic administration. PEG-MGF (PEGylated MGF) conjugates polyethylene glycol (PEG) chains to the peptide, dramatically increasing plasma half-life to several days. This enables systemic administration with once-weekly dosing and produces sustained satellite cell activation throughout the body rather than locally. PEG-MGF is the practical form most community users employ; native MGF is used by some for local site injections immediately post-workout.

Science & Mechanism

Satellite cells, MAPK pathway, and PEGylation

Mechanism of Action

1
Mechanical stress-induced splicing: During exercise or injury, the IGF-1 gene is alternatively spliced to produce the IGF-1Ec mRNA. The Ec domain (E-peptide) is MGF's unique C-terminal extension — a 24 amino acid sequence that is specifically cleaved from the rest of the IGF-1Ec protein and acts as a separate signalling molecule. This E-peptide fragment is what the synthetic MGF peptide replicates.
2
Satellite cell activation via MAPK-Erk1/2: MGF activates quiescent muscle satellite cells — the stem cells that fuse with existing fibres to enable hypertrophy and repair — through the MAPK-Erk1/2 pathway, independently of IGF-1R. This initial activation step precedes IGF-1-mediated differentiation, making MGF and IGF-1/LR3 genuinely complementary: MGF wakes up satellite cells; IGF-1 drives their proliferation and differentiation into mature muscle.
3
Local vs systemic delivery: Native MGF injected at the site of muscle damage or immediately adjacent to trained muscles acts locally before rapid clearance. PEG-MGF distributes systemically and activates satellite cells throughout the body. The choice depends on whether localised injury repair (native MGF, site injection) or broad anabolic stimulus (PEG-MGF) is the goal.
4
PEGylation extends half-life: Conjugation of PEG chains to MGF sterically shields the peptide from proteolytic enzymes and renal clearance, extending plasma half-life from ~5 minutes to several days depending on the PEG molecular weight. This transforms an impractical research tool into a usable once-weekly SubQ compound.
5
Non-redundancy with IGF-1 LR3: Because MGF acts through a different receptor and pathway than IGF-1R, the two have additive effects on satellite cell biology. Community protocols frequently combine PEG-MGF (satellite cell activation) with IGF-1 LR3 (proliferation and differentiation) to target both arms of the hypertrophy cascade simultaneously.
Community Voices

What people report

Bodybuilding ProtocolResearch compound use

"PEG-MGF 200mcg twice weekly for 6 weeks post-injury (partial bicep tear). Combined with BPC-157 and TB-500. Recovery timeline was faster than both previous injuries without peptides. Hard to attribute causation but the combination felt qualitatively different — the affected muscle seemed to remodel more completely."

Male, 34. The combination of PEG-MGF (satellite cell activation), BPC-157 (angiogenesis and growth factor expression), and TB-500 (actin dynamics and cell migration) covers three non-overlapping mechanisms of tissue repair. This triple-stack has become a community standard for significant muscle injuries.

Training Enhancement ReportResearch compound use

"Native MGF 200mcg site-injected into each quad immediately after heavy squats, twice weekly. Within 3 weeks: meaningful increase in quad fullness and recovery speed. The localised effect is distinctly different from systemic peptides — you can feel the difference in the specific muscle."

Male, 27, competitive powerlifter. Site injection of native MGF immediately post-workout is the community's most direct application of the physiological rationale — replicating the local repair signal that exercise itself induces, but at a higher concentration and more sustained presence than endogenous production provides.

Safety First

Risks & considerations

⚠️
Limited human safety data. Generally well-tolerated in community use. The main concerns are proliferative risk over long cycles and purity verification from research sources. As an endogenous splice variant at physiological doses, immune reactions are uncommon. Long-term supraphysiological satellite cell activation has not been characterised in controlled human studies.
Moderate
Proliferative risk over extended use — prolonged satellite cell activation via MAPK-Erk1/2 at supraphysiological levels raises theoretical concern about uncontrolled cellular proliferation in susceptible tissues. Cycle to 4–6 weeks maximum. Contraindicated with active or recent malignancy.
Mild
Injection site reactions — local redness and swelling, particularly with site injections of native MGF adjacent to muscle. Transient and self-resolving.
Unknown
PEG accumulation — PEG chains from PEGylated compounds can accumulate in tissues with prolonged use. The clinical significance at PEG-MGF doses is unknown. Avoid continuous long-term use.
Honest Assessment

Editor's summary

MGF and PEG-MGF occupy a distinct niche — local muscle repair and satellite cell activation through a pathway non-redundant with IGF-1. The physiological rationale is excellent: this is exactly what the muscle produces in response to mechanical damage, and exogenous administration replicates and amplifies that signal. The community evidence for injury recovery and localised hypertrophy is consistent over many years of use.

The choice between native MGF (site injection, local effect, impractical for systemic use) and PEG-MGF (systemic, sustained, once-weekly) depends entirely on the application. Injury recovery with localised target: native MGF + BPC-157 + TB-500. Broad anabolic stimulus alongside IGF-1 LR3: PEG-MGF systemically. The two forms are not interchangeable — they have different pharmacokinetics and use cases.

Verdict
"The body's own post-exercise repair signal — replicated and amplified. Non-redundant with IGF-1 LR3 (different pathway, different cells, additive effect). Native MGF for local site repair; PEG-MGF for systemic satellite cell activation. The injury recovery triple-stack with BPC-157 and TB-500 is one of the most mechanistically sound peptide combinations in the community."